Breast Cancer
-
Forward Look
Improving Breast Cancer Outcomes After SurgeryAntibody-drug conjugate improves survival in people with early-stage HER2-positive breast cancer who have residual disease.
by Susan Kreimer
-
The HER2 SHIFTAntibody-drug conjugate provides an additional treatment option for people with HER2-low breast cancer.
by Kendall K. Morgan
-
Q&A
Creating Tiny Doses of JoyJoelle Kaufman writes about how life’s simple pleasures lifted her spirits during treatment.
by Erin O'Donnell
-
Declining Breast Cancer Mortality in Younger WomenU.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin
-
Musical Toxicity an Effect of Cancer TreatmentStudy finding cancer treatment affects ability to play or sing music highlights need for physical therapy, experts say.
by Kyle Bagenstose
-
Overcoming ResistancePeople with metastatic hormone receptor-positive breast cancer are living longer, thanks to new targeted therapies and endocrine therapies that can be prescribed when treatment resistance develops.
by Kendall K. Morgan
-
Q&A
A Journey of Self-discoveryKailee McGee’s short film explores how a breast cancer diagnosis reshaped how she sees herself.
by Tyler Santora
-
Treating HER2-ultralow Breast CancerFDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.
by Sandra Gordon
-
Screening Options for People With Dense BreastsReports on breast density inform women of their status but raise questions about what to do next.
by Robin Roenker
-
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
